This clinical trial is focused on studying the effects of a treatment called Raludotatug Deruxtecan, also known by its code name DS-6000a. The trial is designed to evaluate the treatment’s effectiveness and safety in people with advanced or metastatic solid tumors. These tumors include certain types of gynecological cancers such as endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer, as well as genitourinary cancers like urothelial cancer and clear cell renal cell carcinoma (ccRCC).
The purpose of the study is to assess how well Raludotatug Deruxtecan works in treating these cancers and to monitor any side effects. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period to observe the treatment’s impact on their cancer and overall health.
Throughout the trial, researchers will focus on understanding how the treatment affects the size and growth of the tumors, as well as any changes in the participants’ health. The study aims to provide valuable information on the potential benefits and risks of using Raludotatug Deruxtecan for these types of cancers, contributing to future treatment options for patients with advanced or metastatic solid tumors.



Belgium
Denmark
France
Italy
Spain